EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib
Condition: Ovarian Cancer
Sponsor: Ellipses Pharma
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients.
Cohort 1 – platinum resistant disease and are PARP inhibitor naïve.
Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.